Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Akums Drugs & Pharma IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 2004 Industry: Pharmaceuticals & Drugs Listed Page

Profile
Issue Size --
Profile
Price Range 646  to  679 per share
Profile
Min Investment ₹679
Profile
Lot Size 1
Profile
Face Value ₹2
Profile
Draft Prospectus --
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Akums Drugs and Pharmaceuticals Limited is a prominent player in the Indian pharmaceutical industry, known for its extensive contract manufacturing capabilities. Founded in 2004 and headquartered in New Delhi, Akums has rapidly expanded to become a leader in pharmaceutical manufacturing and marketing. The company operates over 13 state-of-the-art manufacturing facilities in Haridwar, Uttarakhand, with certifications such as WHO-GMP and ISO, ensuring high-quality standards across its production processes. Akums specializes in manufacturing a diverse range of products, including pharmaceutical formulations, herbal and nutraceutical products, and cosmetics. Their offerings span various therapeutic segments, including anti-diabetic, cardiovascular, pain management, anti-infectives, and dermatology. As a leading contract manufacturer, Akums serves over 600 clients domestically and internationally, providing comprehensive solutions from product development to packaging and logistics. The company's strong emphasis on research and development enables continuous innovation and improvement of its product portfolio, while its rigorous quality assurance practices ensure safety and efficacy. Akums has established a significant market presence, serving both Indian and multinational pharmaceutical companies and exporting products to several countries, thereby enhancing its global footprint. The company is also actively involved in corporate social responsibility initiatives, focusing on healthcare, education, and environmental sustainability. Akums has received numerous awards and recognitions for its excellence in manufacturing, quality, and business practices, solidifying its reputation as a leader in the pharmaceutical industry. Read More

Basic Info

Face Value 2 per share

Price 646  to  679 per share

P/E (x) 30

Sales( Cr.) 4118

PAT( Cr.) 344

EPS 22.6

Draft Prospectus --

Exchange BSE-NSE

Promoter

Company Promoters

Sanjeev Jain Sandeep Jain Akums Master Trust

Pre Issue Share Holding 84.94%

Post Issue Share Holding --%

Listing Details:

Listing Price: 725

Listing Gain: 6.34%

Current Price: 524.5

Gain On Issue: 524.5 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date Jul 30, 2024
Closing Date Aug 01, 2024
Allotment Aug 02, 2024
Refund Aug 05, 2024
Delivery of Shares Aug 05, 2024
Listing Date Aug 06, 2024

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 22 14,938
Retail (Max) 13 286 194,194
S-HNI (Min) 14 308 209,132
S-HNI (Max) 66 1452 985,908
B-HNI (Min) 67 1474 1,000,846

Objective of the Issue

1. Repayment/ prepayment of indebtedness of the company and its Subsidiaries 2. Funding incremental working capital requirements of the company 3. Pursuing inorganic growth initiatives through acquisitions 4. General corporate purposes.

Issue

Category Nos Bid Bid (x)
QIB 20508872 1847644278 90.1x
NII 4101774 172684685 42.1x
Retail 2734516 56877933 20.8x
EMP 0 0 0x
Total 27345162 1734777077 63.4x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Akums Drugs & Pharma Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 1464 1651 1857 1552 2008 2414 2723 3672 3655 4178 4118
Other Income 7 6 9 15 22 27 21 23 90 34 56
Total Income 1471 1657 1866 1567 2030 2442 2744 3695 3745 4212 4174
Total Expenditure 1340 1507 1663 1353 1826 2240 2431 3764 3361 4055 3658
Operating Profit 131 149 204 214 204 202 312 -69 384 157 517
Interest 23 22 16 13 23 20 7 17 46 51 35
Depreciation 31 38 46 52 56 67 70 95 113 126 153
Exceptional Income / Expenses 0 0 0 0 0 -1 -64 -13 -75 -26 17
Profit Before Tax 77 89 143 150 126 114 172 -193 150 -45 345
Provision for Tax 38 44 47 59 58 70 49 58 52 -46 1
Profit After Tax 38 45 96 90 68 44 123 -251 98 1 344
Adjustments 5 17 0 0 0 4 -1 -2 -3 -5 -6
Profit After Adjustments 44 61 96 90 68 48 123 -253 95 -4 338
Adjusted Earnings Per Share 3.4 4.8 7.4 7 5.3 3.3 8.6 -17.7 6.6 -0.3 22.1

Akums Drugs & Pharma Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 494 629 711 795 856 722 885 622 717 709 3047
Minority's Interest 3 12 21 29 35 -2 2 3 6 11 17
Borrowings 78 52 0 17 45 10 1 13 115 78 0
Other Non-Current Liabilities 55 71 50 69 74 576 684 1139 1131 1384 -52
Total Current Liabilities 412 396 417 480 525 730 580 1272 1266 1211 894
Total Liabilities 1042 1161 1200 1389 1535 2037 2152 3050 3235 3393 3905
Fixed Assets 444 501 603 649 652 644 904 1021 1097 1191 1397
Other Non-Current Assets 37 80 23 39 50 143 91 138 214 262 233
Total Current Assets 561 580 574 701 833 1250 1157 1864 1879 1941 2275
Total Assets 1042 1161 1200 1389 1535 2037 2152 3050 3235 3393 3905

Akums Drugs & Pharma Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 21 10 14 7 18 21 92 22 55 52 111
Cash Flow from Operating Activities 72 89 156 157 -23 28 134 32 177 498 465
Cash Flow from Investing Activities -150 -123 -128 -111 -49 -190 -109 -235 -305 -330 -548
Cash Flow from Financing Activities 66 37 -34 -35 75 233 -95 236 125 -108 73
Net Cash Inflow / Outflow -11 4 -7 11 3 71 -70 33 -4 60 -10
Closing Cash & Cash Equivalent 10 14 7 18 21 92 22 55 52 111 101

Akums Drugs & Pharma Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 3.37 4.76 7.39 7 5.26 3.34 8.57 -17.65 6.63 -0.28 22.09
CEPS(Rs) 5.36 6.42 10.93 10.99 9.59 7.71 13.51 -10.92 14.72 8.84 32.48
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 38.22 48.69 55.02 61.49 66.23 50.49 61.83 43.47 50.13 49.59 199.01
Core EBITDA Margin(%) 8.46 8.67 10.44 12.83 9.08 7.21 10.69 -2.5 8.04 2.94 11.18
EBIT Margin(%) 6.81 6.69 8.48 10.46 7.39 5.54 6.57 -4.81 5.38 0.13 9.22
Pre Tax Margin(%) 5.23 5.36 7.65 9.63 6.27 4.71 6.33 -5.26 4.11 -1.08 8.38
PAT Margin (%) 2.61 2.69 5.13 5.82 3.39 1.81 4.53 -6.83 2.68 0.02 8.35
Cash Profit Margin (%) 4.72 5 7.58 9.14 6.17 4.57 7.1 -4.25 5.76 3.03 12.07
ROA(%) 4.05 4.04 8.1 6.99 4.65 2.44 5.89 -9.64 3.11 0.02 9.42
ROE(%) 8.03 7.93 14.25 12.02 8.24 5.53 15.36 -33.3 14.61 0.11 18.3
ROCE(%) 14.55 13.94 18.08 17.35 14.2 13.23 19.05 -18 17.59 0.43 17.83
Receivable days 63.98 58.57 54.24 73.8 73.33 79.73 74.6 70.36 86.36 73.33 71.09
Inventory Days 56.29 60.52 52.19 63.37 51.21 50.37 55.51 57.27 72.52 59.41 58.11
Payable days 60.24 60.52 51.87 77.37 62.78 78.42 82.54 72.46 92.84 78.67 88.12
PER(x) 0 0 0 0 0 0 0 0 0 0 21.49
Price/Book(x) 0 0 0 0 0 0 0 0 0 0 2.38
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 0.17 0.12 0.1 0.1 0.12 0.01 0.01 0.07 0.11 0.06 1.63
EV/Core EBITDA(x) 1.86 1.35 0.93 0.73 1.22 0.14 0.1 -3.9 1.08 1.55 12.98
Net Sales Growth(%) 28.92 12.75 12.49 -16.42 29.37 20.21 12.78 34.87 -0.47 14.32 -1.44
EBIT Growth(%) -26.51 11.09 42.54 2.79 -8.62 -9.93 33.83 -198.62 211.33 -97.29 7018.68
PAT Growth(%) -57.42 16.44 114.53 -5.28 -24.81 -35.84 182.76 -303.24 138.99 -99.19 0
EPS Growth(%) -50.84 41.23 55.41 -5.28 -24.81 -36.56 156.74 -305.86 137.56 -104.25 7932.55
Debt/Equity(x) 0.52 0.34 0.27 0.22 0.31 0.24 0.11 0.58 0.75 0.69 0
Current Ratio(x) 1.36 1.47 1.38 1.46 1.59 1.71 2 1.47 1.48 1.6 2.55
Quick Ratio(x) 0.73 0.74 0.79 0.84 1.08 1.17 1.26 0.9 0.91 1.08 1.78
Interest Cover(x) 4.32 5.01 10.19 12.66 6.59 6.71 26.54 -10.6 4.25 0.11 10.98
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0 0 0 0

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR -1% 4% 11% 11%
Operating Profit CAGR 229% 0% 21% 15%
PAT CAGR 34300% 0% 51% 25%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -8% NA% NA% NA%
ROE Average 18% 11% 3% 6%
ROCE Average 18% 12% 7% 12%

Company Contact Information

Akums Drugs & Pharmaceuticals Ltd.

304 Mohan Place, L S C Saraswati Vihar

IPO Lead Manager(s)

Akums Drugs & Pharmaceuticals Ltd.

Axis Capital Ltd.

Citigroup Global Markets India Pvt Ltd.

ICICI Securities Ltd

Ambit Private Limited

Registrar Info

Akums Drugs & Pharmaceuticals Ltd.

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!